AFFILIATIONS
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 Nanyang Central Hospital, Nanyang, China
3 North China University of Science and Technology Affiliated Hospital, Tangshan, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 Nanyang Central Hospital, Nanyang, China
7 North China University of Science and Technology Affiliated Hospital, Tangshan, China
8 The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
9 Tianjin Medical University Second Hospital, Tianjin, China
10 The First Affiliated Hospital of Nanchang University, Nanchang, China
11 The Second Hospital of Shanxi Medical University, Taiyuan, China
12 The Second Hospital of Shanxi Medical University, Taiyuan, China
13 Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China
14 The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
15 The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
16 The First Hospital of Jilin University, Changchun, China
17 Shanghai Sixth People’s Hospital, Shanghai, China
18 The Affiliated Hospital of Qingdao University, Qingdao, China
19 The First Hospital of Hebei Medical University, Shijiazhuang, China
20 The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
21 The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
22 The Second Affiliated Hospital of Guangxi Medical University, Nanning, China
23 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
24 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
25 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
26 Shanghai Junshi Biosciences Co., Ltd, Shanghai, --- Select One ---, China
27 Shanghai Junshi Biosciences Co., Ltd, Shanghai, --- Select One ---, China
28 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
29 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
30 Shanghai Junshi Biosciences Co., Ltd, Shanghai, --- Select One ---, China
31 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
ABSTRACT
Introduction
Treatment with JAK inhibitors (JAKi) for myelofibrosis (MF) is limited by modest response rates and insufficient tolerability. WJ01024, an oral new generation XPO1 inhibitor, has demonstrated preliminary efficacy in patients with MF in prior study (JS110-002 ), especially in combination with ruxolitinib. JS110-003 was launched to further define the antitumor activity of this combination therapy. Here we report the data from this Phase Ib/II study of WJ01024 combined with ruxolitinib in patients with MF.
Methods
MF patients with splenomegaly who were relapsed/refractory, or intolerant to JAKi were assigned to receive oral WJ01024 60 mg once weekly (first dose: 40 mg) and ruxolitinib ≥ 5 mg twice daily (initial dose was determined by the investigator) per 4-week cycle for both phases Ib and II. The primary endpoints were the safety and pharmacokinetics in phase Ib, and the spleen volume reduction of ≥ 35% [SVR35] at week 24 compared with baseline in phase II. Key secondary endpoints included total symptom score reduction of ≥ 50% [TSS50] at week 24, spleen volume reduction of ≥ 25%[SVR25] at week 24 and at any time, SVR35 at any time.
Results
As of June 11, 2026, 33 patients were enrolled and received study treatment (median age: 62 years [range: 34 - 77]; male: 63.6%; primary MF: 63.6%, post-polycythemia vera MF: 21.2%; post-essential thrombocythermia MF: 15.2%). Of those, 30 patients had relapsed/refractory disease to ruxolitinib and 3 were intolerant to ruxolitinib. Driver mutations at baseline were JAK2 (72.7%), CALR (21.2%), MPL (6.1%), and triple negative (3.0%); 36.4% of the patients had high-molecular risk mutations. Median baseline spleen volume was 1346.9 (range: 372 - 3580) cm3. The most common WJ01024-related adverse events(TRAEs) were nausea (75.8%), platelet count decreased (69.7%), anaemia (54.5%), appetite decreased (45.5%), and vomiting (30.3%). Grade ≥ 3 TRAEs occurred in 10 (30.3%) patients. TRAEs leading to WJ01024 dose interruption and dose reduction occurred in 4 (12.1%) and 6 (18.2%) patients, respectively. No patients discontinued WJ01024 permanently, and no fatal events were observed. Among the 27 patients who completed the 24-week efficacy assessment, 9 (33.3%) achieved SVR35 and 16 (59.3%) achieved SVR25 at any time. The median time to SVR35 and SVR25 were 18.1 weeks (range: 6.1 - 36.1) and 11.9 weeks (range 6.1 - 36.0), respectively. At week 24, 7 (25.9%) patients achieved SVR35 and 13 (48.1%) achieved SVR25; TSS50 were observed in 37.0% of patients. Seventeen patients achieved clinical improvement, yielding an overall objective response rate of 63.0% (17/27). A reduction in bone marrow fibrosis grade from baseline was found in 6 (22.2%) patients. Among the 33 patients, the mean plasma concentrations at 1 hour (± 5 min) post-dose on Cycle 1 Day 1 (C1D1), C2D1, C4D1, and C6D1 were 564.9, 583.1, 532.3, and 547.1 ng/mL, respectively, comparable to WJ01024 60 mg monotherapy.
Conclusions
WJ01024 in combination with ruxolitinib showed promising efficacy and an acceptable safety profile in patients with MF who were relapsed/refractory or intolerant to JAKi therapy, supporting further clinical development of WJ01024 in MF.
DISCLOSURES
Hu Zhou, MD: Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China - Research Funding